DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells

Oncogene RNA helicase DDX6 promotes the process of c-Myc expression in gastric cancer cells

(2018) Kohei Taniguchi et al.   MOLECULAR CARCINOGENESIS

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Japanese gastric cancer treatment guidelines 2014 (ver. 4)

(2016)   Gastric Cancer

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

DDX6 Orchestrates Mammalian Progenitor Function through the mRNA Degradation and Translation Pathways

(2015) Ying Wang et al.   MOLECULAR CELL

Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells

(2014) Nami Yamada et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

(2014) Cecília Durães et al.   VIRCHOWS ARCHIV

Chemically Modified Synthetic microRNA-205 Inhibits the Growth of Melanoma Cells In Vitro and In Vivo

(2013) Shunsuke Noguchi et al.   MOLECULAR THERAPY

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial

(2012) A. F. C. Okines et al.   ANNALS OF ONCOLOGY

Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

(2012) A Gallardo et al.   BRITISH JOURNAL OF CANCER

Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction

(2012) B. E. Phillips et al.   DISEASES OF THE ESOPHAGUS

Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells

(2012) Ryutaro Mori et al.   Gastric Cancer

Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial

(2012) Fei Zhou et al.   World Journal of Surgical Oncology

Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma

(2011) Shi-Yan Yan   WORLD JOURNAL OF GASTROENTEROLOGY

Low frequency of HER2 amplification and overexpression in early onset gastric cancer

(2011) Cathy B. Moelans et al.   CELLULAR ONCOLOGY

Role of anti-oncomirs miR-143 and -145 in human colorectal tumors

(2010) Y Akao et al.   CANCER GENE THERAPY

Trastuzumab in gastric cancer

(2010) Alicia F.C. Okines et al.   EUROPEAN JOURNAL OF CANCER

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

HER-2 amplification is highly homogenous in gastric cancer

(2009) Michael Bilous et al.   HUMAN PATHOLOGY

FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review)

(2009) Katoh   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY

Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

(2008) Henrike E. Karim-Kos et al.   EUROPEAN JOURNAL OF CANCER